WuXi AppTec Executive and Leadership Team

Ge Li, the Chief Executive Officer at WuXi AppTec, directs the overarching strategy and operational execution for the company's extensive research and manufacturing services. Overseeing WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, and WuXi DDSU segments, Ge Li ensures seamless integration across discovery, development, and manufacturing processes for small molecule drugs and advanced therapies. This leadership role involves driving innovation in contract research, development, and manufacturing organization (CRDMO) services, extending from initial discovery through to commercialization. By focusing on synthetic molecular modalities including small molecules, oligonucleotides, and peptides, Ge Li champions the company's mission to accelerate drug development globally. The Chief Executive Officer's strategic vision guides the expansion of WuXi AppTec's capabilities, ensuring robust support for clients in the People's Republic of China, the United States, and Europe. Ge Li's leadership ensures the company remains at the forefront of pharmaceutical innovation.

Minzhang Chen, the Co-Chief Executive Officer at WuXi AppTec, shares executive leadership responsibilities, focusing on strategic growth and operational excellence across the company's global footprint. This role involves driving the expansion of WuXi AppTec's integrated service offerings, which span research, development, and manufacturing for both small molecule drugs and advanced therapies. Minzhang Chen oversees key initiatives aimed at enhancing the company's capabilities in areas such as WuXi Chemistry and WuXi Biology, supporting clients from target discovery through to clinical stages. The Co-Chief Executive Officer's focus is on optimizing the delivery of contract research, development, and manufacturing organization (CRDMO) services, ensuring efficiency and quality for partners in China, the United States, and Europe. Minzhang Chen's leadership contributes significantly to WuXi AppTec's position as a vital partner in the global pharmaceutical ecosystem, facilitating the journey of new medicines from concept to market.

Steve Yang, the Co-Chief Executive Officer at WuXi AppTec, collaborates on the strategic direction and operational management of the company's comprehensive drug discovery and manufacturing services. This executive leadership position involves guiding the expansion of WuXi AppTec's integrated platform, which supports the development of small molecule drugs and advanced therapies across multiple global markets. Steve Yang's responsibilities include overseeing the seamless execution of contract research, development, and manufacturing organization (CRDMO) services, ensuring clients receive end-to-end support from initial research phases to commercial production. The Co-Chief Executive Officer's strategic input is crucial for enhancing capabilities within segments like WuXi Testing and WuXi ATU, thereby accelerating the delivery of innovative medicines. Steve Yang's leadership reinforces WuXi AppTec's commitment to empowering pharmaceutical and biotechnology partners worldwide.

Florence Shi, the Senior Vice President, Chief Financial Officer at WuXi AppTec, manages the company's financial strategy, operations, and reporting across its global business segments. This executive position involves overseeing all financial aspects of WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, and WuXi DDSU, ensuring fiscal health and strategic resource allocation. Florence Shi directs financial planning, investment analysis, and risk management to support WuXi AppTec's continuous growth and expansion in the contract research, development, and manufacturing organization (CRDMO) sector. The Chief Financial Officer's expertise is vital for maintaining financial stability and driving profitability, enabling the company to invest in advanced technologies and expand its service offerings for clients worldwide. Florence Shi's leadership ensures robust financial governance and supports the company's mission to accelerate drug development.

Zhaohui Zhang, the Executive Vice President & Chief Operating Officer (China) at WuXi AppTec, directs the operational execution and strategic implementation of services within the People's Republic of China. This leadership role focuses on optimizing the performance of WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, and WuXi DDSU segments across the domestic market. Zhaohui Zhang oversees the day-to-day operations, ensuring efficiency, quality, and compliance with regulatory standards for contract research, development, and manufacturing organization (CRDMO) services. The Chief Operating Officer (China)'s responsibilities include driving operational excellence, managing resources effectively, and fostering collaboration among teams to support the rapid advancement of small molecule drugs and advanced therapies. Zhaohui Zhang's leadership is crucial for strengthening WuXi AppTec's presence and capabilities within its home market.

Daisy Liu, the President at WuXi AppTec, holds a significant leadership position overseeing key strategic initiatives and operational functions that drive the company's growth and service expansion. This role involves guiding the development and implementation of WuXi AppTec's comprehensive research and manufacturing services, encompassing WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, and WuXi DDSU. Daisy Liu's responsibilities include fostering strong client relationships and ensuring the effective delivery of contract research, development, and manufacturing organization (CRDMO) solutions for small molecule drugs and advanced therapies. The President's strategic vision contributes to enhancing the company's global capabilities and market presence. Daisy Liu's leadership supports WuXi AppTec's mission to accelerate the journey of new medicines from discovery to commercialization.

Richard Connell, the President of WuXi AppTec, directs critical aspects of the company's global operations and strategic development, focusing on enhancing its integrated service platform. This executive position involves overseeing the delivery of comprehensive research, development, and manufacturing services across WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, and WuXi DDSU. Richard Connell's leadership ensures the efficient execution of contract research, development, and manufacturing organization (CRDMO) solutions, supporting the advancement of small molecule drugs and advanced therapies for a global clientele. The President of WuXi AppTec's focus is on driving operational excellence and fostering innovation to meet the dynamic needs of the pharmaceutical and biotechnology sectors. Richard Connell's contributions are vital to WuXi AppTec's mission of accelerating drug discovery and development worldwide.

David Chang, the Chief Technology Officer at WuXi AppTec, spearheads the technological innovation and infrastructure development that underpins the company's extensive research and manufacturing services. This critical role involves architecting and implementing advanced technological solutions across WuXi Chemistry, WuXi Biology, and WuXi ATU, ensuring cutting-edge capabilities for small molecule drug discovery and advanced therapy development. David Chang directs the integration of novel platforms and digital tools that enhance efficiency, precision, and scalability in contract research, development, and manufacturing organization (CRDMO) services. The Chief Technology Officer's vision is instrumental in maintaining WuXi AppTec's competitive edge, enabling the company to offer state-of-the-art solutions to partners in China, the United States, and Europe. David Chang's leadership ensures that WuXi AppTec remains at the forefront of technological advancement in the pharmaceutical services sector.

Erich Koch, the Chief Operations Officer at WuXi AppTec, oversees the global operational strategies and execution across the company's diverse service segments, including WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, and WuXi DDSU. This executive role is pivotal in ensuring the seamless delivery of contract research, development, and manufacturing organization (CRDMO) services, supporting the discovery and production of small molecule drugs and advanced therapies. Erich Koch focuses on enhancing operational efficiency, implementing best practices, and driving continuous improvement throughout the global network. The Chief Operations Officer's leadership ensures that WuXi AppTec maintains high standards of quality and reliability for its international client base. Erich Koch's strategic oversight is essential for scaling operations and meeting the evolving demands of the pharmaceutical and biotechnology industries worldwide.

Xiaozhong Liu, the Executive VP & Head of the Strategic Project Office at WuXi AppTec, leads the strategic planning and execution of key projects that advance the company's research and manufacturing capabilities. This role is central to coordinating efforts across WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, and WuXi DDSU, ensuring alignment with corporate objectives. Xiaozhong Liu oversees the management of complex projects, driving efficiency and innovation in the delivery of contract research, development, and manufacturing organization (CRDMO) services for small molecule drugs and advanced therapies. The Head of the Strategic Project Office's focus is on optimizing project lifecycles and ensuring successful outcomes for clients globally. Xiaozhong Liu's leadership is instrumental in translating strategic goals into tangible operational achievements, supporting WuXi AppTec's mission to accelerate pharmaceutical innovation.